Ikanomycin (IKA) also blocks glycolysis by targeting HK2, reduces tumor volume in mice with PC xenografts, and enhances the chemotherapeutic response of PC cells to GEM (Jiang et al., 2020). The gene discussed is HK2; the disease is pachyonychia congenita.